Dermatology Times

MARCH 24, 2025

Participants from the parent DELTA 1 and 2 studies maintained their disease control and observed a decrease in pain and itch over 52 weeks of treatment.

Eczema 41

Eczema Safety Treatments 41

The Dermatology Digest

JANUARY 13, 2025

Results from multiple clinical trials showed that rezpegaldesleukin safely and dose-dependently increased Tregs and rapidly improved measurable exploratory disease outcomes in patients with moderate-to-severe AD that were largely durable for at least 36 weeks after ceasing treatment, demonstrating proof-of-concept in this indication.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

The Dermatology Digest

JANUARY 15, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE) with limited systemic exposure, according to two studies presented at the 2024 Winter Clinical Dermatology Conference in Honolulu, Hawaii. This trial included samples from 313 people on active treatment.

Safety 36

Safety Eczema Dermatology Treatments 36

Aesthetics Advisor

MARCH 10, 2024

Infants of mothers randomized to cut out eggs, milk, and fish were significantly less likely to have eczema even years later. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disease. Previously, I talked about the safety and efficacy of other, more natural treatments. But what about diet?

Eczema 36

Eczema Diet Dermatitis Document 36

The Dermatology Digest

FEBRUARY 9, 2024

Brian Hilberdink, Leo Pharma’s EVP of North America, chatted with TDD about the significance of this study and the deleterious effect that chronic hand eczema can have on a person’s quality of life. Patients living with chronic hand eczema are impacted in their everyday lives and experience social, psychological, and physical effects.

Eczema 36

Eczema Marketing Dermatitis Safety 36

The Dermatology Digest

JANUARY 21, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE), with limited systemic exposure, according to two studies presented at the 2024 Maui Dermatology conference. What’s more, delgocitinib cream 20 mg/g was well-tolerated over 16 weeks, and no safety concerns were identified.

Safety 36

Safety Eczema Social Media Dermatology 36

The Dermatology Digest

MAY 16, 2024

million, five-year National Institutes of Health (NIH) U01 grant to investigate dupilumab (Dupixent, Sanofi & Regeneron) as a treatment for children with alopecia areata. Current treatment options for alopecia areata harbor negative side effects for long-term use. Dr. Guttman. “If

Eczema 69

Eczema Dermatitis Clinic Safety 69

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

SEPTEMBER 26, 2024

The safety profile was consistent with that previously reported, the study showed. Safety is not an issue. At Week 56, IGA 0/1 was achieved in 47% and 49% and EASI-75 in 73% and 79% of patients with previous nemolizumab and nemolizumab-naïve patients, respectively. Improvements in itch, sleep, and QoL were also observed over time.

Dermatitis 74

Dermatitis Safety Management Eczema 74

The Dermatology Digest

DECEMBER 15, 2023

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. achieved an Eczema Area and Severity Index (EASI) of 75, 90, and 100, respectively. In the switchers, 47.6%

Treatments 36

Treatments Dermatitis Pharmaceutical Eczema 36

The Dermatology Digest

JANUARY 30, 2024

Five investigators have received funding through the 2023 PeDRA Research Grants, Career Bridge Research Grant, Pediatric Alopecia Areata Challenge Grant, and Childhood Eczema Challenge Grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

The Dermatology Digest

JANUARY 11, 2024

of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. Vtama cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. Fully 80.7%

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

MARCH 7, 2024

The drug demonstrated significant and clinically relevant improvements in itch, patient-assessed quality-of-life indicators, inflammation, and safety, with minimal side effects and strong patient tolerability when compared to baseline.

Safety 36

Safety Dermatitis Eczema Clinic 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

JANUARY 23, 2024

The two 48-week randomized, placebo-controlled double-blind, phase 3 studies, ARCADIA 1 and ARCADIA 2 ( N =787) comprised a 16-week initial treatment period followed by a 32-week maintenance period. Safety was assessed throughout the study. in ARCADIA 2 when compared with placebo.

Dermatitis 36

Dermatitis Safety Sustainability Eczema 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Therapy Dermatitis Eczema 36

Eminence Organics

JANUARY 19, 2024

Desincrustation is a deep cleansing treatment that's effective in preparing oily or congested skin for extractions. This key treatment leaves the skin with improved skin texture and health, making it an ideal choice for oily or congested skin. Enhances Skin Care Absorption: Desincrustation prepares the skin for subsequent treatments.

Pores 52

Pores Sebum Extractions Dark Spots 52

The Dermatology Digest

DECEMBER 19, 2023

Over three months of treatment, patients received 250mg ADX-629, administered orally twice daily. The primary endpoint of the clinical trial was safety and tolerability. Relative to baseline, over three months of treatment, improvement was observed in all patients. Statistical significance was achieved for improvement in EASI.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5% Importantly, EASI-90 was observed in 22.4%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

MARCH 11, 2024

Food and Drug Administration (FDA) recently accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Eczema Dermatology 36

The Dermatology Digest

MARCH 11, 2024

Sanofi’s investigational OX40-ligand blocker amlitelimab produces sustained improvement in the signs and symptoms of atopic dermatitis (AD) in adults who previously responded and continued treatment and sustained off-drug improvements in those who stopped treatment. of patients withdrawn from treatment, the study showed.

Sustainability 36

Sustainability Dermatitis Safety Hospital 36

The Dermatology Digest

APRIL 22, 2024

Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% Treatment was well-tolerated and no new safety signals were identified.

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

US Dermatologt Partners

MARCH 27, 2024

While dermatologists and research scientists haven’t decided on one name for this cutting-edge treatment, red light therapy is quickly gaining popularity thanks to the skin-rejuvenating results researchers are noting in research studies. Improves psoriasis , rosacea , acne , and eczema side effects. What is Red Light Therapy?

Therapy 41

Therapy Treatments Dermatology Collagen 41

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. “It is important to have systemic treatments approved for CHE, both with and without atopic dermatitis.

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

The Dermatology Digest

SEPTEMBER 25, 2024

307) 67.8 (320) 320) 75.9 (323) 323) 4 to 7.2 severe) 10.5 (152) 152) 47.2 (142) 142) 63.2 (136) 136) Minimal Disease Activity (MDA; EASI 90 + WP-NRS 0/1) 0 to <1 (no-to-mild) 3.1 (97) 108) 1 to <4 (moderate) 2.0 (304) 304) 22.3 (319) 319) 37.5 (320) 320) 4 to 7.2 severe) 0.7 (150) 150) 24.8 (141) 141) 37.8 (135) 283) 25.3 (296) 296) 38.0 (295)

Dermatitis 36

Dermatitis Dermatology Eczema Safety 36

The Dermatology Digest

DECEMBER 20, 2023

Tim Raducha-Grace Named Chief Platform Officer at Zerigo Health Tim Raducha-Grace is the new Chief Platform Officer at Zerigo Health, a connected phototherapy platform that couples a handheld Narrow-band ultraviolet B (NB-UVB) light device with a smartphone app and team of care providers to allow patients to treat psoriasis and eczema at home.

Dermatology 36

Dermatology Surgery Eczema Office 36

Kind of Stephen

AUGUST 3, 2022

It’s marketed as a soothing ingredient and sometimes, often illegally, as a disinfectant, anti-inflammatory, acne treatment, or something that can “trigger an immune boost…repair and heal skin”. Some dermatologists might recommend a patient with eczema to take a 5-to-10-minute bath in very dilute bleach (0.005%). But what is it?

Sanitation and Sterilization 52

Sanitation and Sterilization Sanitation Eczema Skincare 52

The Dermatology Digest

JULY 25, 2024

In the ARCADIA trials, AD patients saw statistically significant improvements in as early as one week after nemolizumab treatment initiation The studies appear in The Lancet. Reducing itch within just one week of treatment could significantly ease the burden of disease.” Based on the results of the ARCADIA 1 and 2 trials, the U.S.

Dermatitis 28

Dermatitis Safety Eczema Clinic 28

The Dermatology Digest

OCTOBER 5, 2023

“It all boils down to stress,” said Keira Barr, MD, who presented “Beauty & The Beast: Stress, Trauma, Skin Disease & A Somatic Approach to Healing,” during the “Mind Body Therapies as Treatment Strategy in Dermatology: What is the Evidence?” This [can trigger] or exacerbate conditions like psoriasis, acne, and eczema.

Safety 36

Safety Social Media Therapy Sun Protection 36

The Dermatology Digest

DECEMBER 18, 2023

The new AD guidelines also: • Highlight the safety of the topical calcineurin inhibitors with typical usage once or twice daily. Recommend dupilumab for patients 6 months of age or older with moderate-severe AD refractory, intolerant, or unable to use mid-potency topical treatment, or tralokinumab for similar patients ages 12 years and older.

Dermatitis 36

Dermatitis Partnerships Therapy Diet 36

US Dermatologt Partners

JANUARY 24, 2024

It’s important to address these painful symptoms as they arise, but managing psoriasis requires a treatment plan to prevent and address the effects of this condition, as well as the comorbidities that are common for those who struggle with psoriasis. Talk to a Professional Today Dealing with psoriasis and its comorbidities?

Management 36

Management Skin Health Medical Dermatology 36